- Home
- APLT
as 12-17-2024 4:00pm EST
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 140.8M | IPO Year: | 2019 |
| Target Price: | $6.60 | AVG Volume (30 days): | 10.8M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.03 - $10.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -86.64% | Revenue Growth (next year): | 5117.00% |
Latest Applied Therapeutics Inc. News
APLT Breaking Stock News: Dive into APLT Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
MT Newswires
16 days ago
Applied Therapeutics Faces Uncertainty After US FDA Rejects NDA for Govorestat in Galactosemia, UBS Says
Zacks
16 days ago
Company News for Dec 2, 2024
MT Newswires
16 days ago
UBS Downgrades Applied Therapeutics to Neutral From Buy, Cuts Price Target to $2 From $13
TipRanks
18 days ago
Applied Therapeutics CRL a ‘major setback,’ says William Blair
TipRanks
18 days ago
Applied Therapeutics downgraded to Sector Perform from Outperform at RBC
GuruFocus.com
18 days ago
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%
Zacks
19 days ago
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
Compare APLT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLT Applied Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.